dengue

France’s bioMérieux has secured European CE marking for three fully automated immunoassays for dengue, the company announced Wednesday.

Performed on the company’s Vidas family platforms, the Vidas Dengue NS1 Ag, Anti-Dengue IgM and Anti-Dengue IgG are “cost-effective and suitable for low- and middle-income countries,” according to the press release.

The company plans to add a chikungunya assay to its diagnostic offerings, per the announcement.

Takeda has asked the European Medicines Agency to approve its tetravalent dengue vaccine candidate, the company announced last week. In parallel, the agency will consider recommending the shot for countries outside the European Union through the EU-M4all (previously Article 58) procedure, according to the press release.

Takeda said it plans to seek additional approvals for TAK-003 this year in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand…

Covid-19 dominated the 39th J. P. Morgan Healthcare Conference (JPM), held virtually this week instead of at its customary haunt, San Francisco’s Westin St. Francis. Beyond much coronavirus chatter, the event also featured one major M&A announcement (Sanofi touting its $1 billion Kymab buy) and additional vaccine news from companies including GSK (for RSV), Moderna (for flu, HIV and Nipah) and Takeda (for dengue).

BioNTech CEO Uğur Şahin announced the German company’s plans to…

Bayer launched on Monday its Fludora Co-Max dual-action space spray solution for combating insecticide-resistant Aedes mosquito-borne arboviruses including chikungunya, dengue and Zika.

The spray combines two compounds (transfluthrin and flupyradifurone) and can be diluted with water to “maintain efficacy over greater distances” and reduce environmental impact, the press release said. Fludora Co-Max has been available in Côte d’Ivoire since November; Bayer will introduce it in other…

Britain’s Emergex Vaccines announced last week that it has raised $11 million from “new and existing investors” to develop its synthetic T-cell vaccines (delivered using a thermostable microneedle patch), including candidates for Covid-19, dengue and pandemic influenza. The company raised $11 million in Series A financing in January, in part to advance its Phase 1 dengue shot.

Takeda CEO Christophe Weber told Reuters in an interview last week that vaccines could join gastroenterology, neuroscience, oncology, plasma-derived therapies and rare diseases as a sixth “key business” for the Japanese drugmaker.

Takeda currently has a quadrivalent dengue shot (TAK-003) in Phase 3, a norovirus vaccine in Phase 2, a Zika candidate in Phase 1 and a chikungunya shot in preclinical.

The company has also struck deals to produce 250 million doses of Novavax’s Covid-19…

New Delhi-based Panacea Biotec announced last week that DengiAll, its tetravalent recombinant chimeric vaccine candidate against dengue fever, has completed Phase 1/2 trials. After a single dose of the live-attenuated vaccine, “more than 80% of the participants showed more than a [trivalent] response and ~95% showed a multivalent response,” the company’s press release said.

Brazil’s Instituto Butantan, Britain’s Emergex, Merck, Serum Institute of India and Japan’s Takeda are also in…

A Pan American Health Organization (PAHO) study attributed a 75% reduction in chikungunya cases in sections of a Brazilian municipality to the introduction of Wolbachia-infected A. aegypti mosquitoes, PAHO announced last week, noting that the data are preliminary.

A PAHO team conducted the research in collaboration with the World Mosquito Program (WMP) and Fiocruz, comparing chikungunya incidence in parts of the city of Niterói where Wolbachia-carrying mosquitoes were released to…

Oxitec secured final approval to deploy its genetically modified Aedes aegypti mosquitoes in the Florida Keys, the University of Oxford spinout announced last week. The demonstration project will release “Friendly” A. aegypti males modified to exclusively generate live male offspring when they mate with wild-type females.

The company announced in May that a similar project in Brazil suppressed up to 95% of the dengue-carrying mosquitoes following 13 weeks of treatment, as compared to…

Mentions:

The Lancet published positive results this week from a Phase 1 trial of London-based Imutex’s universal mosquito-borne disease vaccine, AGS-v, which was found safe and induced a strong immune response in volunteers. The shot targets mosquito bite saliva and is designed to protect against multiple mosquito-borne diseases like dengue, malaria and Zika, according to a press release from Open Orphan, an Imutex co-owner.

Imutex’s next-generation candidate, AGS-v PLUS, is in Phase 1 trials…